Kinexus Announces New Phosphoprotein Screening Service Thursday, October 21, 2004 Kinexus Announces New Phosphoprotein Screening Service http://www.kinexus.com Vancouver, BC, October 22, 2004-- Kinexus Bioinformatics Corporation, a Canadian proteomics company that provides unique immunoblotting services to over 500 academic and biopharmaceutical laboratories, reported the successful launch of its sixth Kinetworks Phospho-Site Screening Service, KPSS 6.0. The new screen, developed in collaboration with Stressgen Bioreagents in Victoria, Canada, was designed to simultaneously detect the presence and relative quantities of 34 critical protein phosphorylation sites in humans and diverse animal model systems. The Kinetworks screening services are a cost-effective solution for the identification of disease diagnostic markers and drug targets, delineation of mechanisms of drug action and toxicity, and validation of animal models for testing drug leads. Kinexus currently tracks over 180 protein kinases, 150 phospho-sites in kinase targets, and 120 other signaling proteins that regulate cell proliferation, stress responses and apoptosis. Mapping the human phosphoproteome is one of the most promising and challenging endeavors facing the health industry today. Defects in protein phosphorylation are linked to over 400 human diseases, and the protein kinases that carry out this important process have emerged as the second leading class of targets for drug discovery. The Kinetworks approach for the detection of phosphoproteins is unique in the marketplace and unrivalled for its cost, sensitivity, reliability and speed. It has already been used by hundreds of clients to reveal striking differences in the expression levels and phosphorylation patterns of signaling proteins within diverse model systems and disease states. The KPSS 1.3 Phospho-Site Screen previously uncovered promising research leads, such as a 150-fold increase in the phosphorylation of adducin found in the spinal cord of ALS patients compared to patient matched controls. This approach has also been used to identify several promising protein kinase drug targets including Jun N-terminal kinase and Polo-like kinase-1, which if suppressed may block the reproduction of tumor cells without many of the negative side effects commonly associated with existing cancer drugs. All publications referencing the Kinetworks technology can be viewed at www.kinexus.ca. Kinexus Bioinformatics Corporation is a private, biopharmaceutical company engaged in the research and development of innovative proteomics methods to discover and exploit the relationships of signaling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in disease diagnosis, drug development and personalized therapies to improve human health. For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.   See All News Releases From This Company View Company Website Email To A Friend Printer-Friendly Format